December 2, 2021
Krystal Biotech Raises $200 Million in Public Offering to Advance Redosable Gene Therapies
Read More
December 2, 2021
AviadoBio Raises $80 million to Advance Neurodegenerative Gene Therapy Platform
Read More
December 2, 2021
Tune Therapeutics Launches with Epigenomic Control Platform to Master Gene Networks
Read More
November 22, 2021
BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets
Read More
November 18, 2021
BridgeBio Secures Up to $750 Million in Debt Financing to Advance Rare Disease Pipeline
Read More
November 17, 2021
Chroma Medicine Launches with $125 Million to Advance Epigenetic Editing Platform
Read More
November 17, 2021
Mirum Sells Rare Pediatric Disease Priority Review Voucher
Read More
November 10, 2021
Takeda Boosts Dealmaking Numbers in October as Other Rare Disease Activity Slows
Read More
November 10, 2021
Mekonos Raises $25 Million to Overcome Cell and Gene Therapy Delivery Hurdles
Read More
November 9, 2021
Blade Therapeutics Reverse Mergers into SPAC to Become a Public Company
Read More
November 9, 2021
Arbor Closes $215 Million Financing to Advance Next Generation Precision Editing Therapeutics
Read More
November 9, 2021
Alltrna Launches with $50 Million to Unlock Transfer RNA Biology, Treat Disease with a Single tRNA Medicine
Read More
Load More
X